文献速递消化与肝胆胰病理

2026年上消化道病理学新进展:关键更新与演变挑战

What's new in upper gastrointestinal pathology: Key updates and evolving challenges in 2026.
PubMed 文献 · Hum Pathol · 2025-12-25

本文综述了第6版WHO消化系统肿瘤分类中上消化道病理的关键更新,包括将食管表皮样化生列为独立章节、修改胃化生性和异型增生性病变的分类方法,并概述了免疫治疗相关上消化道黏膜损伤的新模式,尤其是利妥昔单抗和CAR-T细胞治疗相关改变,旨在为病理学家提供实用指南。

要点

  • 第6版WHO分类将食管表皮样化生列为独立章节。
  • 胃化生性和异型增生性病变的分类方法有所修改。
  • 利妥昔单抗和CAR-T治疗可导致类似感染或免疫疾病的上消化道黏膜改变。

核心结论

  • 第6版WHO分类对上消化道病理进行了重要更新,趋向简化术语和统一分级系统。
  • 免疫治疗相关上消化道损伤模式需仔细组织学评估以避免误分类。

研究设计与样本

  • 综述,总结第6版WHO分类上消化道更新及治疗相关损伤模式。

主要发现

  • 食管表皮样化生被列为独立章节。
  • 胃化生性和异型增生性病变的分类方法被修改。
  • 利妥昔单抗和CAR-T细胞治疗与独特的上消化道黏膜改变相关,可类似感染或免疫疾病。

临床怎么用

  • 病理学家应熟悉第6版WHO分类更新以准确诊断上消化道病变。
  • 识别利妥昔单抗和CAR-T相关黏膜损伤模式,避免误诊为感染或免疫疾病。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Diagnostic pathology of the upper gastrointestinal tract continues to evolve as molecular insights, clinical practices, and updated international standards improve our understanding of disease. The World Health Organization (WHO) classification of digestive system tumors, now in its 6th edition, includes several important changes, including incorporating esophageal epidermoid metaplasia as a separate section, and modifying the approach to metaplastic and dysplastic gastric lesions. These updates reflect a broader trend toward simplified terminology, clearer definitions of precursor lesions, and more consistent grading systems across the digestive tract. At the same time, increased use of immunotherapy has introduced new patterns of injury. Beyond immune checkpoint inhibitors, several agents, including rituximab and chimeric antigen receptor T-cell therapy have been associated with distinctive upper-GI mucosal alterations that can resemble infectious or immunologic diseases. Failure to recognize these patterns of injury can carry significant clinical implications, including treatment delay or discontinuation, and require careful histologic evaluation to avoid misclassification. This review summarizes select upper-GI updates from the 6th edition of the WHO classification and outlines emerging therapy-related injuries with a focus on rituximab- and CAR-T-associated changes. The aim is to provide a practical and contemporary guide for pathologists navigating these evolving diagnostic challenges.

来源:Hum Pathol,查看原文。版权归原作者所有。

引用

  1. Ortiz Requena D, Montgomery EA. What's new in upper gastrointestinal pathology: Key updates and evolving challenges in 2026. Hum Pathol. 2025. PMID: 41455587. doi:10.1016/j.humpath.2025.106025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。